Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Uniphar increases profit in H1 2026 and confirms EBITDA target for 2028
Uniphar reports adjusted EPS of EUR 0.109 in H1 2026 (+11.2%), gross profit of EUR 236.5m (+7.7%) and EBITDA of EUR 61.1m (+6.2%). Return on capital employed (ROCE) was 14.7%, and free cash flow was negative at EUR -47m, which is attributed to timing effects in working capital. Management reaffirmed the mid‑term target of EUR 200m EBITDA by 2028 and expects double‑digit growth in Pharma and continued growth in Medtech; the commissioning of the new Greenogue 2 distribution centre has been delayed to February 2027. » More on de.investing.com
Uniphar executives trade shares from remuneration plan
Senior executives of Uniphar carried out share purchases and sales under the company’s share-based remuneration plan through the Uniphar plc Employee Benefit Trust. CEO Gerard Rabbette bought 111,088 ordinary shares and sold 233,068 ordinary shares; CFO Timothy Dolphin bought 74,059 and sold 155,378 ordinary shares — all transactions at €3.8629 per share. After the transactions Rabbette holds 7,334,772 and Dolphin holds 5,610,856 ordinary shares. The dealings were reported on Euronext Dublin via Intertrust Trustee (Ireland) Limited as trustee and are based on a disclosure under Article 19 of the Market Abuse Regulation. » More on de.investing.com
Uniphar schedules general meeting for 7 May and sends annual report
Uniphar has scheduled its annual general meeting for 7 May 2026 at 11:00 in the premises of William Fry LLP in Dublin and has sent the annual report for the year ended 31 December 2025 to shareholders. Shareholders may attend in person, vote by proxy, or follow the meeting by telephone as listeners only; questions must be submitted in writing with the shareholder reference number by 5 May 2026 at 17:00. The notice, proxy form and annual report are available on the company website and for inspection at the registered office during normal business hours. » More on de.investing.com
Uniphar reports 9% organic gross profit growth and beats 2025 earnings expectations
Uniphar recorded 9% organic gross profit growth in 2025 and adjusted earnings per share that rose by around 21%, outperforming the 14% consensus forecast. Drivers included lower financing costs and effects from a €35m share buyback programme. Net debt at year-end stood at 1.5x EBITDA, roughly €90m below analyst expectations, supported by positive working capital. Uniphar confirms its target to reach €200m EBITDA by 2028 (including €20m from M&A) and sets 2026 growth targets for its divisions: Pharma (double-digit), Medtech (high single-digit) and Supply Chain & Retail (low single-digit); the new logistics centre and ERP remain on schedule for the summer. » More on de.investing.com
Santhera agrees exclusive distribution deal for AGAMREE with Uniphar for five GCC states
Santhera Pharmaceuticals has signed an exclusive distribution partnership with Uniphar for AGAMREE (Vamorolone) in the United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain; sales via a named-patient program are due to start in Q1 2026, with broader commercial distribution expected after approval at the end of 2026. Santhera will receive sales-based compensation and stresses that the agreement is intended to accelerate access to the therapy for DMD patients in the region. The drug is already approved in several regions and Santhera names additional licensing partners for certain markets. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 1.57B | - |
| Gross profit | 216.56M | - |
| Net profit | 19.73M | - |
| EBITDA | 57.87M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.13B |
Number of shares | 259.57M |
52-week high/low | €5.14 - €3.53 |
Dividend yield | 0.47% |
Dividends TTM | €0.0205 |
Beta | 1.16 |
P/E ratio | 21.01 |
PEG ratio | -1.31 |
P/B ratio | 2.62 |
P/S ratio | 0.36 |
Company profile
Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, and internationally. The company operates through three divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division offers outsourced sales, marketing, and multichannel account management services to pharmaco-medical manufacturers; and distribution and support services to medical device manufacturers. The Product Access division provides on demand services, which provides access to pharmaco-medical products and treatments by developing valuable relationships and interactions between manufacturers and other healthcare stakeholders; and exclusive access services that offers bespoke distribution partnerships to pharmaceutical partners for key brands. The Supply Chain & Retail division engages in pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons; and operates a network of pharmacies under the Life, Allcare, and Hickey's brands. It also offers pharmacy support, pharmaceutical supply chain, specialist nursing and infusion, medical device distribution, healthcare technology, data intelligence and consultancy services, pharmaceutical advisory, medical affairs, and online pharmacy and product fostering services, as well as data solutions for pharma industry. Uniphar plc was founded in 1967 and is headquartered in Dublin, Ireland.
| Name | UNIPHAR PLC EO -,08 |
| CEO | Gerard Rabbette |
| Headquarters | Dublin,
du Ireland |
| Website | |
| IPO | 07/17/2019 |
| Employees | 3,500 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | UPR.L |
Frankfurt | 0NR.F |
London | UPR.L |
MĂĽnchen | 0NR.MU |
DĂĽsseldorf | 0NR.DU |